Welcome to our dedicated page for Nika Pharmaceuticals SEC filings (Ticker: NIKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to regulatory filings and related disclosures for Nika Pharmaceuticals, Inc. (NIKA), a healthcare company in the pharmaceutical sector. While no recent SEC filings are listed in the provided data, Nika Pharmaceuticals’ public communications outline its focus on immune-related therapies, generic drugs, dietary supplements, and the ITV-1 program for AIDS.
For investors and researchers, formal filings such as annual reports (Form 10-K) and quarterly reports (Form 10-Q), when available, can offer structured information on Nika Pharmaceuticals’ business segments, risk factors, intellectual property, and manufacturing plans. In the company’s case, these documents are particularly relevant for understanding its reported portfolio of six injectable drugs, four tablet-form drugs, and eleven dietary supplements, as well as its collaboration with Immunotech Laboratories BG on IPF-based products like ITV-1.
Regulatory filings can also shed light on distribution agreements and geographic exposure. Nika Pharmaceuticals has publicly described exclusive distribution arrangements for ITV-1 in the United Arab Emirates, Ukraine, Iraq, Jordan, Syria, and Nigeria, and has discussed plans related to a production building in Sofia Province, Bulgaria, through its subsidiary Nika Europe, Ltd. When present, filings may provide additional detail on the terms of such agreements, associated risks, and any contingent obligations.
On Stock Titan, NIKA-related filings are paired with AI-powered summaries that explain key sections in plain language. As new documents are posted to EDGAR, they can be reflected here with concise overviews of complex topics such as clinical program disclosures, manufacturing investments, and distribution strategies. Users can review these materials alongside company news to form a more complete picture of Nika Pharmaceuticals’ regulatory and operational profile.
Nika Pharmaceuticals, Inc. filed its Q3 2025 report, showing no revenue and a net loss of $7,999 for the quarter ended September 30, 2025 (nine months: $39,309). Cash was $6,287 and current liabilities were $284,164, resulting in a stockholders’ deficit of $260,539. The company disclosed “substantial doubt” about its ability to continue as a going concern.
Operations were funded by related-party advances, including $45,000 during the nine months. At quarter-end, amounts due included $45,000 to Nika Europe, $205,164 to the CEO, and $34,000 to Nika Pharmaceuticals LTD, all non‑interest bearing and due on demand. The company continued accounting for a common control merger and issued 13,230,000 of the 204,205,027 common shares to be issued under that agreement. Common shares outstanding were 1,039,836,001 as of November 7, 2025.
Disclosure controls were deemed not effective due to a lack of an audit committee and separation of duties. The report also notes a production agreement with Nika Europe for ITV‑1 with a framework price of $580 per set, tied to factory completion.
FAQ
What is the current stock price of Nika Pharmaceuticals (NIKA)?
What is the market cap of Nika Pharmaceuticals (NIKA)?
